Saphris Related Published Studies
Well-designed clinical trials related to Saphris (Asenapine)
Long-term effects of asenapine or olanzapine in patients with persistent negative
symptoms of schizophrenia: a pooled analysis. [2013]
Asenapine as adjunctive treatment for acute mania associated with bipolar
disorder: results of a 12-week core study and 40-week extension. [2012]
A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. [2011.03]
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine. [2011.01]
Role of sublingual asenapine in treatment of schizophrenia. [2011]
A double-blind, randomized study comparing the efficacy and safety of sertindole
and risperidone in patients with treatment-resistant schizophrenia. [2011]
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. [2010.06]
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. [2010.04]
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia
or schizoaffective disorder. [2010]
Asenapine versus olanzapine in acute mania: a double-blind extension study. [2009.12]
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. [2009.11]
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. [2009.11]
Asenapine. [2009.09.01]
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. [2007.10]
Well-designed clinical trials possibly related to Saphris (Asenapine)
Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. [2010.09]
Adjunctive use of atypical antipsychotics for treatment-resistant generalized
anxiety disorder. [2010]
Other research related to Saphris (Asenapine)
Efficacy and tolerability of asenapine for acute mania in bipolar I disorder:
meta-analyses of randomized-controlled trials. [2013]
Management of schizophrenia: clinical experience with asenapine. [2013]
Asenapine versus olanzapine in people with persistent negative symptoms of
schizophrenia. [2012]
Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. [2011.07.13]
Asenapine pharmacokinetics in hepatic and renal impairment. [2011.07.01]
Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? [2011.07]
Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. [2011.06.20]
Valproate Reduces the Glucuronidation of Asenapine Without Affecting Asenapine Plasma Concentrations. [2011.05.31]
Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects. [2011.05.06]
Metabolism and excretion of asenapine in healthy male subjects. [2011.04]
Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. [2011.03.01]
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. [2011.03]
Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. [2011]
Asenapine: a new antipsychotic option. [2011]
Comparison of QTc data analysis methods recommended by the ICH E14 guidance and
exposure-response analysis: case study of a thorough QT study of asenapine. [2011]
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. [2010.12.25]
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. [2010.11]
Evaluation of the clinical efficacy of asenapine in schizophrenia. [2010.08]
Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. [2010.07]
Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. [2010.05]
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. [2010.04]
Effect of absorption site on the pharmacokinetics of sublingual asenapine in
healthy male subjects. [2010]
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week
extension study. [2010]
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial
in patients with acute exacerbation of schizophrenia. [2010]
Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. [2009.12]
Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. [2009.12]
Asenapine. [2009.11]
Asenapine effects in animal models of psychosis and cognitive function. [2009.11]
Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. [2009.07]
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. [2009.01]
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. [2008.02]
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale. [2007]
Other possibly related research studies
Gateways to clinical trials. [2010.04]
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. [2008]
Acute and long-term treatment of mania. [2008]
Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. [2008.09.04]
Gateways to clinical trials. [2007.05]
Gateways to clinical trials. [2007.03]
Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. [2007]
Update on newer antipsychotic drugs. [2011.04]
Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. [2011.09.28]
Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. [2011.10.08]
The role of serotonin receptors in the action of atypical antipsychotic drugs. [2011.02]
Dual inhibition: a novel promising pharmacological approach for different disease conditions. [2011.04]
[The quest for the pharmacological treatment of schizophrenia: from conventional neuroleptics to atypical antipsychotics and beyond]. [2010.09]
Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. [2011.03]
Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. [2011.01]
A systematic review of meta-analyses of the efficacy of oral atypical
antipsychotics for the treatment of adult patients with schizophrenia. [2012]
Comparative efficacy and acceptability of antimanic drugs in acute mania: a
multiple-treatments meta-analysis. [2011]
A review of the pharmacology, efficacy and tolerability of recently approved and
upcoming oral antipsychotics: an evidence-based medicine approach. [2013]
Efficacy of second generation antipsychotics in treating acute mixed episodes in
bipolar disorder: a meta-analysis of placebo-controlled trials. [2013]
Atypical antipsychotics in the treatment of children and adolescents with
pervasive developmental disorders. [2014]
An update on the treatment of mixed bipolar states: what is new in 2013? [2014]
|